Overview
Exploratory assessment of the efficacy and safety of gemcitabine-albumin-based paclitaxel chemotherapy combined with SBRT in the treatment of newly diagnosed borderline resectable and locally advanced unresectable pancreatic cancer patients with sequential investigator selection (IC).
Description
The question of how to administer adequate chemotherapy to synchronize SBRT treatment strategy to maximize the benefits of neoadjuvant therapy for improved prognosis of patients with borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer is a challenging and debatable issue. No studies have yet evaluated the efficacy of split-course SBRT as the neoadjuvant chemoradiotherapy regimen. The investigators aimed to study whether neoadjuvant chemotherapy plus split-course SBRT results in better outcomes in BRPC and LAPC patients.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years old and ≤ 70 years old.
- Histologically or cytologically confirmed adenocarcinoma of the pancreas.
- Borderline resectable or locally advanced pancreatic cancer proven by imaging examinations via multidisciplinary approaches according to NCCN guidelines
- No prior chemotherapy or radiotherapy
- ECOG performance status of 0 or 1.
- Without distant metastasis
- The maximum diameter of the tumor must not exceed 5 cm
- Acceptable hematology parameters: a. Absolute neutrophil count (ANC) ≥1500 cell/mm3 b. Platelet count ≥100,000/mm3 c. Hemoglobin (Hgb)≥9 g/dL
- Acceptable blood chemistry levels: a. AST/SGOT and ALT/SGPT≤2.5× upper limit of normal range (ULN) b. Total bilirubin≤1.5 ULN c. Alkaline phosphatase≤2.5× ULN d. Serum albumin>3 g/dL e. Serum creatinine≤1.5 ULN
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
Exclusion Criteria:
- Age < 18 years old and > 70 years old. Prior anticancer therapy for pancreatic carcinoma.
- Presence of or history of metastatic pancreatic adenocarcinoma.
- Patients who had surgeries, chemotherapy, or other treatments before inclusion.
- Any other malignancy within 5 years prior to enrollment
- History of allergy or hypersensitivity to nab-paclitaxel or gemcitabine or any of their excipients.
- Peripheral sensory neuropathy Grade > 1
- Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders.
- Pregnant or breast feeding.
- Patients enrolled in other clinical trials or incompliant with regular follow-up
- Unwillingness or inability to comply with study procedures.